Docetaxel trihydrate is the trihydrate form of docetaxel. It is used to treat breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer. Among its listed roles, it functions as a antineoplastic agent. It is a hydrate and a secondary alpha-hydroxy ketone. It includes a member of docetaxel anhydrous. It is grouped under the following drug class(es): Microtubule inhibitors, Taxanes and Terpenes. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Docetaxel hydrate and Taxotere (TN). Its PubChem CID is 148123.
Docetaxel trihydrate
| CAS No | 148408-66-6 |
|---|---|
| Molecular Formula | C43H59NO17 |
| Molecular Weight | 861.9 g/mol |
| Synonyms | [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate;trihydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Docetaxel trihydrate is the trihydrate form of docetaxel. It is used to treat breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer.
The listed CAS number is 148408-66-6.
The listed molecular formula is C43H59NO17.
The listed molecular weight is 861.9 g/mol.
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate;trihydrate.
The source lists Docetaxel hydrate and Taxotere (TN).